Список проголосовавших за комментарий " <table class="BriefingDataTable" border="0" cellspacing="0" cellpadding="0"><tr> <td class="tickerColumn"> </td> <td class="articleColumn">Amgen: CHRS Neulasta biosimilar 'competitor' bullish on their upcoming approval date — RBC (181.05)RBC notes CHRS has a Neulasta biosimilar FDA approval decision date in a few months. There is some Street nervousness over this given Neulasta is AMGN's 2nd biggest drug at $4B+ so it's competition to one of their largest and most profitable drugs....Mylan (<strong>MYL</strong>) also mentions their Neulasta biosimilar in slide decks with possible approval for November 2017...although overall, Street assumes that a biosimilar may come and launch by YE-17 and consensus models AMGN Neulasta down -10% for 2018. Their call is CHRS might get approval but this is somewhat already expected so not a material impact this year (despite headline/sentiment risk) and the bigger thesis is whether PCSK9 can pick up the pace in 2017-2018 and whether Romo FDA approval in July 2017 offers.</td> </tr></table>"